Cyclosporine ophthalmic 0.05% — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Dry Eye (Keratoconjunctivitis sicca)

• Artificial tears (carboxymethylcellulose
• Artificial tears (carboxymethylcellulose 0.5%)

About Cyclosporine ophthalmic 0.05%

Struggling with chronic dry eyes? Cyclosporine ophthalmic 0.05 offers a powerful solution to relieve discomfort and restore natural tear production. At TheDrugClub, we believe effective treatment should be accessible. Cyclosporine ophthalmic 0.05 is a prescription eye drop primarily used to treat chronic dry eye disease, also known as keratoconjunctivitis sicca. This condition occurs when your eyes don't produce enough tears, or the tears they produce aren't of the right quality, leading to persistent irritation, burning, stinging, redness, and a gritty sensation. Left untreated, chronic dry eye can even damage the surface of your eye. By addressing the underlying cause, cyclosporine ophthalmic 0.05 helps alleviate these bothersome symptoms, allowing for greater comfort and improved eye health. Unlike artificial tears that provide temporary lubrication, cyclosporine ophthalmic 0.05 works differently. It belongs to a class of medications called immunomodulators. Chronic dry eye often involves inflammation on the surface of the eye, which can suppress natural tear production. Cyclosporine works by reducing this inflammation, specifically by inhibiting certain

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Cyclosporine ophthalmic 0.05% is approved for (FDA label)

RESTASIS MULTIDOSE ® ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs. RESTASIS MULTIDOSE is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 21, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Cyclosporine ophthalmic 0.05% (FDA label)

Ophthalmic emulsion containing cyclosporine 0.05% (0.5 mg/mL) Cyclosporine ophthalmic emulsion 0.05% (0.5 mg/mL) ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 7224d810-bb96-4682-a942-3355e6e8061a. SPL document ID: 6b6704de-6a92-4d21-8cb5-fbd1c2f3c489. Label effective date: August 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Cyclosporine ophthalmic 0.05% (FDA label)

The following serious adverse reactions are described elsewhere in the labeling: Potential for Eye Injury and Contamination [ see Warnings and Precautions (5.1) ] The most common adverse reaction following the use of cyclosporine ophthalmic emulsion 0.05% was ocular burning (17%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 7224d810-bb96-4682-a942-3355e6e8061a. SPL document ID: 6b6704de-6a92-4d21-8cb5-fbd1c2f3c489. Label effective date: August 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Cyclosporine ophthalmic 0.05% (FDA label)

RESTASIS MULTIDOSE is contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation [ see Adverse Reactions (6.2) ] . Hypersensitivity ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 7224d810-bb96-4682-a942-3355e6e8061a. SPL document ID: 6b6704de-6a92-4d21-8cb5-fbd1c2f3c489. Label effective date: August 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Cyclosporine ophthalmic 0.05% (FDA label)

To avoid the potential for eye injury and contamination, be careful not to touch the bottle tip to your eye or other surfaces. ( 5.1 ) 5. 1 Potential for Eye Injury and Contamination Be careful not to touch the bottle tip to your eye or other surfaces to avoid potential for eye injury and contamination. 5.2 Use with Contact Lenses RESTASIS MULTIDOSE should not be administered while wearing contact lenses. Patients with decreased tear production typically should not wear contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS MULTIDOSE ophthalmic emulsion.

Source: FDA prescribing information (DailyMed). Set ID: 7224d810-bb96-4682-a942-3355e6e8061a. SPL document ID: 6b6704de-6a92-4d21-8cb5-fbd1c2f3c489. Label effective date: August 21, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.